3-Ethoxycarbonyl-4-formyl-2-methyl-1-n-propylpyrrol | 67982-56-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯
• 英文名称: 3-Ethoxycarbonyl-4-formyl-2-methyl-1-n-propylpyrrol
• 英文别名: 4-formyl-2-methyl-1-propyl-pyrrole-3-carboxylic acid ethyl ester；Ethyl 4-formyl-2-methyl-1-propylpyrrole-3-carboxylate
• CAS: 67982-56-3
• 化学式: C₁₂H₁₇NO₃
• 分子量: 223.272
• InChiKey: QEEVGIJQNSYDIP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  16
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  48.3
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-Ethoxycarbonyl-4-formyl-2-methyl-1-n-propylpyrrol 在 乙醇 、 sodium hydroxide 作用下， 以88%的产率得到4-Formyl-2-methyl-1-propylpyrrole-3-carboxylic acid
  参考文献：
  名称：

  [EN] PIPERIDINE DERIVATIVES FOR USE IN THE TREATMENT OF PANCREATIC CANCER
  [FR] DÉRIVÉS DE PIPÉRIDINE UTILISABLES DANS LE TRAITEMENT DU CANCER DU PANCRÉAS

  摘要：

  本发明涉及具有更好的细胞生长抑制活性的新型哌啶衍生物，特别是对PANC-1癌细胞培养物比FK866具有更好的抑制活性。因此，本发明涉及式（I）的化合物，其中Ar1为芳基或杂环芳基，可以选择地由一个、两个或三个从低碳烷基、低碳氧基、甲酰基、羟基、被低碳氧基或羟基取代的低碳烷基所取代；A为CnH2n、CnH2n-2或CnH2n-4，其中n=4,5,6,7；B为=N-CN、氧（=O）、硫（=S）；D为NH、-CH=CH-；Ar2为芳基或杂环芳基，可以选择地由一个、两个或三个卤素取代；其中，如果B为氧（=O），Ar1和Ar2不同时为苯基和吡啶-3-基；B和D不同时为=N-CN和-CH=CH-，或其药学上可接受的盐、拉氏混合物或其对应的对映体和/或光学异构体。式（I）的化合物及其药学可用的加盐具有有价值的药理学性质。具体而言，已发现本发明的化合物，单独或与其他治疗活性化合物结合，具有作为化疗药物的活性，特别是对抗癌症和更特别是胰腺癌的活性。

  公开号：

  WO2018024907A1

文献信息

• PIPERIDINE DERIVATIVES FOR USE IN THE TREATMENT OF PANCREATIC CANCER
  申请人：Centre Hospitalier Universitaire Vaudois (CHUV)

  公开号：EP3279192A1

  公开（公告）日：2018-02-07

  The present invention relates to novel piperidine derivatives having better cell growth inhibitory activities toward PANC-1 cancer cell cultures than FK866. Accordingly, the present invention relates to compounds of formula I, wherein Ar1 is aryl or heteroaryl, which are optionally substituted by one, two or three substituents selected from lower alkyl; lower alkoxy; formyl; hydroxyl; lower alkyl substituted by lower alkoxy or hydroxyl; A is CnH2n, CnH2n-2 or CnH2n-4, wherein n=4,5,6,7; B is =N-CN, oxo (=O), thio (=S); D is NH, -CH=CH-; Ar2 is aryl or heteroaryl which are optionally substituted by one, two or three halogen substituents; wherein, if B is oxo (=O), Ar1 and Ar2 are not simultaneously phenyl and pyridine-3-yl; B and D are not simultaneously =N-CN and -CH=CH-, or a pharmaceutically acceptable salt, a racemic mixture or its corresponding enantiomers and/or optical isomers. The compounds of formula I and their pharmaceutically usable addition salts possess valuable pharmacological properties. Specifically, it has been found that the compounds of the present invention, alone or in combination with other therapeutic active compounds, have an activity as chemotherapeutic agents against pancreatic cancers.

  本发明涉及新型哌啶衍生物，其对 PANC-1 癌细胞培养物的细胞生长抑制活性优于 FK866。因此，本发明涉及式 I 的化合物，其中 Ar1 是芳基或杂芳基，可任选被一个、两个或三个取代基取代，这些取代基选自低级烷基；低级烷氧基；甲酰基；羟基；被低级烷氧基或羟基取代的低级烷基；A 是 CnH2n、CnH2n-2 或 CnH2n-4，其中 n=4、5、6、7；B 是 =N-CN、氧代（=O）、硫代（=S）；D是NH、-CH=CH-；Ar2是芳基或杂芳基，可任选被一个、两个或三个卤素取代基取代；其中，如果B是氧代（=O），Ar1和Ar2不同时是苯基和吡啶-3-基；B和D不同时是=N-CN和-CH=CH-，或药学上可接受的盐、外消旋混合物或其相应的对映体和/或光学异构体。式 I 化合物及其药用加成盐具有宝贵的药理特性。具体地说，已经发现本发明的化合物，单独或与其他治疗活性化合物结合，具有作为化疗剂对抗胰腺癌的活性。
• Piperidine derivatives for use in the treatment of pancreatic cancer
  申请人：CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS CHUV

  公开号：US10894785B2

  公开（公告）日：2021-01-19

  The present invention relates to novel piperidine derivatives having better cell growth inhibitory activities toward cancer cell cultures and, more particularly, PANC-1 cancer cell cultures than FK866. Accordingly, the present invention relates to compounds of formula I, wherein Ar1 is aryl or heteroaryl, which are optionally substituted by one, two or three substituents selected from lower alkyl; lower alkoxy; formyl; hydroxyl; lower alkyl substituted by lower alkoxy or hydroxyl; A is CnH2n, CnH2n-2 or CnH2n-4, wherein n=4,5,6,7; B is ═N—CN, oxo (═O), thio (═S); D is NH, —CH═CH—; Ar2 is aryl or heteroaryl which are optionally substituted by one, two or three halogen substituents; wherein, if B is oxo (═O), Ar1 and Ar2 are not simultaneously phenyl and pyridine-3-yl; B and D are not simultaneously ═N—CN and —CH═CH—, or a pharmaceutically acceptable salt, a racemic mixture or its corresponding enantiomers and/or optical isomers. The compounds of formula I and their pharmaceutically usable addition salts possess valuable pharmacological properties. Specifically, it has been found that the compounds of the present invention, alone or in combination with other therapeutic active compounds, have an activity as chemotherapeutic agents against cancer and, more particularly, pancreatic cancers.

  本发明涉及新型哌啶衍生物，该衍生物对癌细胞培养物，尤其是 PANC-1 癌细胞培养物具有比 FK866 更好的细胞生长抑制活性。因此，本发明涉及式 I 的化合物，其中 Ar1 是芳基或杂芳基，可任选被一个、两个或三个取代基取代，这些取代基选自低级烷基；低级烷氧基；甲酰基；羟基；被低级烷氧基或羟基取代的低级烷基；A 是 CnH2n、CnH2n-2 或 CnH2n-4，其中 n=4、5、6、7；B 是═N-CN、氧代（═O）、硫代（═S）；D是NH、-CH═CH-；Ar2是芳基或杂芳基，可任选被一个、两个或三个卤素取代基取代；其中，如果B是氧代（═O），Ar1和Ar2不能同时是苯基和吡啶-3-基；B和D不能同时是═N-CN和-CH═CH-，或药学上可接受的盐、外消旋混合物或其相应的对映体和/或光学异构体。式 I 化合物及其药用加成盐具有宝贵的药理特性。具体地说，已经发现本发明的化合物，单独或与其它治疗活性化合物结合使用，具有作为化疗剂对抗癌症，特别是胰腺癌的活性。